Document:

Exhibit 10.41

 

SUBSCRIPTION AGREEMENT

 

This
SUBSCRIPTION AGREEMENT (this “Agreement”) is made as of the latest date set forth on the signature page
hereof between Fennec Pharmaceuticals Inc. (the “Company”) and the undersigned (the “Subscriber”).

 

WITNESSETH:

 

WHEREAS the Company
desires to offer and issue for sale on a private placement basis (the “Offering”) of (i) 1,092,828 common shares
in the capital of the Company (the “First Closing Shares”), anticipated to occur on or about April 8, 2016
or such other date as the Company and the Subscriber may agree (the “First Closing Date”) and (ii) 1,538,751
common shares in the capital of the Company (the “Second Closing Shares”, with the sum of First Closing Shares
and Second Closing Shares being referred to as the “Shares”), anticipated to occur within two (2) business
days of receipt of certain regulatory approval or such other date as the Company and the Subscriber may agree (the “Second
Closing Date”, which together with the First Closing Date shall constitute a “Closing”, as the context
requires), each at a price per Share of USD$1.90 and representing an aggregate purchase price of $5,000,000.10 (the “Purchase
Price”). A summary of the terms of the Offering is set forth in Schedule “A” to this Agreement. Such
summary is qualified in its entirety by the terms and conditions set forth in this Agreement; and

 

WHEREAS unless otherwise
stated, all dollar amounts in this Agreement refer to United States Dollars; and

 

WHEREAS, the Subscriber
desires to purchase Shares on the terms and conditions hereinafter set forth.

 

NOW, THEREFORE, in
consideration of the premises and the mutual representations and covenants hereinafter set forth, the parties hereto do hereby
agree as follows:

 

I.           SUBSCRIPTION
FOR SHARES AND REPRESENTATIONS BY SUBSCRIBER

 

1.1           Subject
to the terms and conditions hereinafter set forth, the Subscriber hereby irrevocably purchases for itself and agrees to purchase
from the Company, and the Company agrees to sell to the Subscriber, the Shares for an aggregate purchase price equal to the Purchase
Price. The Purchase Price is payable by wire transfer of immediately available funds at the time of entering into this Agreement
to an account designated by LaBarge Weinstein LLP, counsel to the Company (“Company Counsel”), to be held in
escrow and shall be released at each Closing (as defined herein) by Company Counsel to an account designated by the Company in
accordance with the terms and conditions of this Agreement. In the event that each Closing does not occur as contemplated by the
terms of this Agreement, Company Counsel shall return the applicable Purchase Price held in escrow to the Subscriber by means
of wire transfer of immediately available funds within two (2) business days of such determination.

 

1.2           The
Subscriber hereby warrants and represents that it recognizes that the purchase of the Shares involves a high degree of risk including,
but not limited to, the following: (a) an investment in the Company is highly speculative and only investors who can afford the
loss of their entire investment should consider investing in the Company and the Shares; (b) the Subscriber may not be able to
liquidate its investment; and (c) transferability of the Shares is limited.

 

    	 	 	 

     

    

 

1.3           The
Subscriber represents that it (i) is an “accredited investor” as such term is defined in Rule 501(a) of Regulation D
promulgated under the Securities Act of 1933, as amended (the “Act”), as indicated by the Subscriber’s
responses to the questions contained in Article IX hereof, and by reason of its business and financial experience and the business
and financial experience of those persons it may have retained to advise it with respect to its investment in the Shares it, together
with such advisors, has such knowledge, sophistication and experience in business and financial matters that it is capable of
evaluating the merits and risks of the prospective investment; (ii) is an “accredited investor” as such term is defined
in National Instrument 45-106 – Prospectus Exemptions, of the Canadian Securities Administrators and the Subscriber
has completed the Accredited Investor Certificate attached hereto as Schedule “C” and (iii) complies
with the requirements of all applicable securities laws in its jurisdiction that is other than the United States and Canada (the
“International Jurisdiction”) and has completed the Accredited Investor Certificate attached hereto as Schedule
“D”.

 

1.4           The
Subscriber hereby acknowledges and represents that: (a) the Subscriber has knowledge and experience in business and financial
matters, prior investment experience, including investment in securities that are unregistered, or the Subscriber, at its own
risk and expense, has employed the services of a “purchaser representative” (as defined in Rule 501(h) of Regulation D),
attorney and/or accountant to read all of the documents furnished or made available by the Company to the Subscriber to evaluate
the merits and risks of such an investment on the Subscriber’s behalf; (b) the Subscriber recognizes the highly speculative
nature of this investment; and (c) the Subscriber is able to bear the loss of its entire investment.

 

1.5           The
Subscriber represents that (i) the Subscriber was contacted regarding the sale of the Shares by the Company, or a Company agent,
with whom the Subscriber had a prior substantial pre-existing relationship and (ii) no Shares were offered or sold to it by means
of any form of general solicitation or general advertising, and in connection therewith, the Subscriber did not receive any general
solicitation or general advertising including, but not limited to: (A) any advertisement, article, notice or other communication
published in any newspaper, magazine or similar media or broadcast over television or radio, whether closed circuit, or generally
available; or (B) through attendance at any seminar meeting or industry investor conference whose attendees were invited by any
general solicitation or general advertising.

 

1.6           The
Subscriber hereby acknowledges that the Offering has not been reviewed by the United States Securities and Exchange Commission
(the “SEC”) nor any U.S. state or Canadian provincial securities regulatory authority (“Securities
Regulatory Authority”) as the Offering is intended to be exempt from the registration requirements of Section 5 of the
Act, pursuant to Regulation D thereunder and from the registration requirements of applicable state “blue sky”
securities laws or regulations. The Subscriber understands that the Shares have not been registered under the Act or under any
U.S. state or Canadian provincial securities or “blue sky” laws or regulations by reason of a claimed exemption that
depends, in part, upon the Subscriber’s investment intention and agreement not to sell, pledge, assign or otherwise transfer
or dispose of the Shares unless they are registered under the Act and under any applicable state securities or “blue sky”
laws or regulations or unless an exemption from such registration is available, subject to Section 1.10 herein. Without limiting
the foregoing, the Company acknowledges and agrees that a Subscriber may from time to time pledge pursuant to a bona fide margin
agreement with a registered broker-dealer or grant a security interest in some or all of the Shares to a financial institution
that is an “accredited investor” as defined in Rule 501(a) under Regulation D and who agrees to be bound by the provisions
of this Agreement and, if required under the terms of such arrangement, such Subscriber may transfer pledged or secured Shares
to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion
of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall
be required of such pledge. At the Subscriber’s expense, the Company will execute and deliver such reasonable documentation
as a pledgee or secured party of the Subscriber may reasonably request in connection with a pledge or transfer of the Shares.

 

    	 	-2-	 

     

    

 

1.7           The
Subscriber hereby represents that the Subscriber is purchasing the Shares for the Subscriber’s own account and not with
a view toward the resale or distribution to others. The Subscriber, if an entity, further represents that it was not formed for
the purpose of purchasing the Shares.

 

1.8           The
Subscriber understands that Rule 144 (“Rule 144”) promulgated under the Act requires for non-affiliates,
among other conditions, a one (1) year holding period prior to the resale in the United States of securities of an issuer that
is not a reporting issuer under the Securities Exchange Act of 1934, as amended, acquired in a non-public offering without having
to satisfy the registration requirements under the Act. The Subscriber understands and hereby acknowledges that except as set
forth herein the Company is under no obligation to register any of the Shares under the Act or any state securities or “blue
sky” laws.

 

1.9           The
Subscriber further understands and agrees that it shall not sell the Shares to a purchaser in any province of Canada at any time
within the four (4) month period following the respective date of their issuance and any subsequent purchaser outside of Canada
before the end of that period must agree to comply with this restriction for the remainder of such period. The Subscriber further
agrees that if it decides to offer, sell or otherwise transfer, pledge or hypothecate all or any part of the Shares, it will not
offer, sell or otherwise transfer, pledge or hypothecate any of such Shares (other than pursuant to an effective registration
statement under the Act), directly or indirectly unless an offer and sale or other disposition is:

 

(a)            made
in accordance with an effective registration statement under the Act covering such disposition; or

 

(b)           to
the Company; or

 

(c)           made
outside the United States in accordance with the requirements of Rule 904 of Regulation S under the Act; or

 

(d)           made
in a transaction that does not require registration under the Act or any applicable United States state laws, rules and regulations
governing the offer and sale of securities, and it has theretofore furnished to the Company an opinion of counsel to that effect;
provided, that no opinion shall be required for any sale pursuant to Rule 144, or pursuant to any bona fide pledge in connection
with a margin account.         

 

1.10         The
Subscriber consents to the placement of a legend on any certificate or other document evidencing the Shares indicating that such
Shares have not been registered under the Act or any state securities or “blue sky” laws and setting forth or referring
to the restrictions on transferability and sale thereof contained in this Agreement. The Subscriber is aware that the Company
will make a notation in its appropriate records with respect to the restrictions on the transferability of such Shares. The legend
to be placed on each certificate shall be in form substantially similar to the following:

 

UNLESS PERMITTED UNDER SECURITIES
LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE THE DATE THAT IS 4 MONTHS AND A DAY AFTER APRIL 8,
2016.

 

    	 	-3-	 

     

    

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE ARE LISTED ON THE TORONTO STOCK EXCHANGE (“TSX”); HOWEVER, THE SAID SECURITIES
CANNOT BE TRADED THROUGH THE FACILITIES OF TSX SINCE THEY ARE NOT FREELY TRANSFERABLE, AND CONSEQUENTLY ANY CERTIFICATE REPRESENTING
SUCH SECURITIES IS NOT “GOOD DELIVERY” IN SETTLEMENT OF TRANSACTIONS ON TSX.

 

THE SECURITIES REPRESENTED HEREBY
HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THE HOLDER HEREOF,
BY PURCHASING SUCH SECURITIES, AGREES FOR THE BENEFIT OF THE ISSUER THAT SUCH SECURITIES MAY BE OFFERED, SOLD OR OTHERWISE TRANSFERRED
ONLY (A) TO THE ISSUER, (B) OUTSIDE THE UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE ACT, OR (C) IN ACCORDANCE
WITH AN EFFECTIVE REGISTRATION STATEMENT OR PURSUANT TO ANOTHER EXEMPTION FROM REGISTRATION AFTER PROVIDING A REASONABLY SATISFACTORY
LEGAL OPINION TO THE ISSUER.

 

Provided
that if the Shares are being sold pursuant to Section 1.9(c) above, in the case of a
resale to a purchaser in Canada, following the date which is four (4) months and a day after the date of issuance to the Subscriber,
the Company covenants and represents that the legend may be removed by providing a declaration to the transfer agent for the Shares
of the Company substantially as attached hereto as Schedule “B” (or as the Company may prescribe from time
to time) upon the sale of the Shares by the Subscriber.

 

1.11         The
Subscriber understands that the Company, at its sole discretion, reserves the unrestricted right, without further documentation
or agreement on the part of the Subscriber, to reject or limit any purchase, to accept purchases for fractional Shares and to
close the Offering to the Subscriber at any time and that the Company will issue stop transfer instructions to its transfer agent
with respect to such Shares.

 

1.12         The
Subscriber hereby represents that the address of the Subscriber furnished by Subscriber on the signature page hereof is the Subscriber’s
principal residence if the Subscriber is an individual or its principal business address if it is a corporation or other entity
and that Subscriber is not resident in any province of Canada. If the Subscriber is resident outside of the United States, the
Subscriber hereby represents that the Subscriber is resident in the International Jurisdiction specified in the address set out
on Subscriber’s signature page to this Agreement and that:

 

(a)           the
Subscriber is knowledgeable of, or has been independently advised as to, the applicable securities laws of the International Jurisdiction
which would apply to this subscription, if there are any;

 

(b)           the
securities laws of the International Jurisdiction applicable to the Subscriber do not require the Company to file a prospectus
or similar document or to register the Shares or to make any filings or seek any approvals of any kind whatsoever in respect of
the sale of the Shares to the Subscriber from any regulatory authority in the International Jurisdiction;

 

(c)            the
delivery of this Agreement by the Company and the Subscriber and the issuance of the Shares to the Subscriber complies with all
applicable securities laws of the International Jurisdiction and will not cause the Company to become subject to any disclosure,
prospectus, registration or reporting requirements under any such securities laws; and

 

    	 	-4-	 

     

    

 

(d)           the
Subscriber will, if requested by the Company, deliver to the Company a certificate or opinion of local counsel from the International
Jurisdiction which will confirm the matters referred to in subparagraphs (b) and (c) above to the satisfaction of the Company,
acting reasonably.

 

1.13         The
Subscriber represents that the Subscriber has full power and authority (corporate, statutory and otherwise) to execute and deliver
this Agreement and to purchase the Shares. This Agreement constitutes the legal, valid and binding obligation of the Subscriber,
enforceable against the Subscriber in accordance with its terms, subject to laws of general application relating to bankruptcy,
insolvency and the relief of debtors and rules of law governing specific performance, injunctive relief or other equitable remedies,
and to limitations of public policy.

 

1.14         If
the Subscriber is a corporation, partnership, limited liability company, trust, employee benefit plan, individual retirement account,
Keogh Plan, or other tax-exempt entity, it is authorized and qualified to invest in the Company and the person signing this Agreement
on behalf of such entity has been duly authorized by such entity to do so.

 

1.15         The
Subscriber is not a Registered Representative of a Financial Industry Regulatory Authority (“FINRA”) member
firm.

 

1.16         

(a)           The
Subscriber agrees not to issue any public statement with respect to the Subscriber’s investment or proposed investment in
the Company or the terms of any agreement or covenant between them and the Company without the Company’s prior written consent
(which consent shall not be unreasonably withheld, conditioned or delayed), except such disclosures as may be required under applicable
law or under any applicable order, rule or regulation.

 

(b)           The
Subscriber acknowledges that this Agreement requires the Subscriber to provide certain personal information to the Company. Such
information is being collected by the Company for the purposes of completing the Offering, which includes, without limitation,
determining the Subscriber's eligibility to purchase the Shares under applicable securities laws, preparing and registering certificates
representing the Shares to be issued to the Subscriber and completing filings required by any Securities Regulatory Authority.
The Subscriber’s personal information may be disclosed by the Company to: (a) any applicable Securities Regulatory Authority;
(b) the Company's registrar and transfer agent; (c) Canada Revenue Agency; (d) any applicable stock exchange or over-the-counter
market (including the TSX); and (e) the Company’s advisors, including legal counsel, and may be included in record books
in connection with the Offering. By executing this Agreement, the Subscriber is deemed to be consenting to the foregoing collection,
use and disclosure of the Subscriber's personal information.

 

(c)           The
Subscriber consents to the filing of copies or originals of any of the Subscriber’s documents described in Section 1.16(b)
hereof as may be required to be filed with any Securities Regulatory Authority in connection with
the transactions contemplated hereby.

 

(d)          If
the Subscriber is a resident of or otherwise subject to applicable securities laws of Ontario, the Subscriber acknowledges that
it has been notified by the Company (a) of the delivery to the Ontario Securities Commission (the “OSC”) of
the full name, residential address and telephone number of the Subscriber, the number and type of securities purchased, the total
purchase price, the exemption relied upon and the date of distribution; (b) that this information is being collected indirectly
by the OSC under the authority granted to it under applicable securities laws; (c) that this information is being collected for
the purposes of the administration and enforcement of the Securities Law of Ontario; and (d) that the Administrative Assistant
to the Director of Corporate Finance can be contacted at Suite 1903, Box 55, 20 Queen Street West, Toronto, Ontario M5H 3S8 or
at (416) 593-8086 regarding any questions about the OSC’s indirect collection of this information and further acknowledges
that it has authorized the indirect collection of this information by the OSC.

 

    	 	-5-	 

     

    

 

(e)          The
Subscriber represents and warrants that the funds representing the aggregate Purchase Price which will be paid by the Subscriber
to the Company for the Shares hereby subscribed for will not represent proceeds of crime for the purposes of the Proceeds of
Crime (Money Laundering) and Terrorist Financing Act (Canada) (the “PCMLA”) and the Subscriber acknowledges
that the Company may in the future be required by law to disclose the Subscriber's name and other information relating to this
Agreement and the Subscriber’s subscription hereunder, on a confidential basis, pursuant to the PCMLA. To the best of its
knowledge (a) none of the subscription funds to be provided by the Subscriber (i) have been or will be derived from or related
to any activity that is deemed criminal under the law of Canada, the United States of America, or any other jurisdiction, or (ii)
are being tendered on behalf of a person who has not been identified to the Subscriber, and (b) it shall promptly notify the Company
if the Subscriber discovers that any of such representations ceases to be true, and to provide the Company with appropriate information
in connection therewith.

 

1.17         Except
for Four Partners Advisory SIM S.p.A., the Subscriber represents and warrants that it has not engaged, consented to or authorized
any broker, finder or intermediary to act on its behalf, directly or indirectly, as a broker, finder or intermediary in connection
with the transactions contemplated by this Agreement. The Subscriber hereby agrees to indemnify and hold harmless the Company
from and against all fees, commissions or other payments owing to any such person or firm acting on behalf of the Subscriber hereunder.

 

1.18         The
Subscriber agrees to hold the Company and its directors, officers, employees, affiliates, controlling persons and agents and their
respective heirs, representatives, successors and assigns harmless and to indemnify them against all liabilities, costs and expenses
incurred by them as a result of (a) any sale or distribution of the Shares by the Subscriber in violation of the Act or any applicable
state securities or “blue sky” laws; or (b) any false representation or warranty or any breach or failure by the Subscriber
to comply with any covenant made by the Subscriber in this Agreement (including the Confidential Investor Questionnaire contained
in Article IX herein) or any other document furnished by the Subscriber to any of the foregoing in connection with this transaction.

 

1.19         The
Subscriber understands, acknowledges and agrees with the Company that, except as otherwise set forth herein, the subscription
hereunder is irrevocable by the Subscriber, that, except as required by law, the Subscriber is not entitled to cancel, terminate
or revoke this Agreement or any agreements of the Subscriber hereunder and that this Agreement and such other agreements shall
survive the death or disability of the Subscriber and shall be binding upon and inure to the benefit of the parties and their
heirs, executors, administrators, successors, legal representatives and permitted assigns. If the Subscriber is more than one
person, the obligations of the Subscriber hereunder shall be joint and several and the agreements, representations, warranties
and acknowledgments herein contained shall be deemed to be made by and be binding upon each such person and his/her heirs, executors,
administrators, successors, legal representatives and permitted assigns.

 

1.20         The
Subscriber understands, acknowledges and agrees with the Company that the Offering is intended to be exempt from registration
under the Act pursuant to the provisions of Regulation D thereunder, which is in part dependent upon the truth, completeness
and accuracy of the representations made by the Subscriber herein.

 

    	 	-6-	 

     

    

 

1.21         The
Subscriber acknowledges that the information contained in this Agreement or otherwise made available to the Subscriber is confidential
and non-public and agrees that all such information shall be kept in confidence by the Subscriber and neither used by the Subscriber
for the Subscriber’s personal benefit (other than in connection with this Agreement, as supplemented) nor disclosed to any
third party for any reason, unless such disclosure is required by applicable law or a court judgment, order or decree, notwithstanding
that the Subscriber’s subscription may not be accepted by the Company; provided, however, that this obligation shall not
apply to any such information that (i) is part of the public knowledge or literature and readily accessible at the date hereof,
(ii) becomes part of the public knowledge or literature and readily accessible by publication (except as a result of a breach
of this provision) or (iii) is received from third parties (except third parties who disclose such information in violation
of any confidentiality agreements or obligations, including, without limitation, any subscription or other similar agreement entered
into with the Company).

 

1.22         The
Subscriber understands, acknowledges and agrees with the Company that: (a) the Company may terminate the Offering or reject any
subscription at any time in its sole discretion and the execution of this Agreement by the Subscriber or solicitation of the investment
contemplated hereby shall create no obligation on the part of the Company to accept any subscription or complete the Offering;
(b) no federal, provincial or state agency or authority has made any finding or determination as to the accuracy or adequacy of
the Offering documents or as to the fairness of the terms of the Offering nor any recommendation or endorsement of the Shares
(any representation to the contrary is a criminal offense); and (c) in making an investment decision, the Subscriber must rely
on its own examination of the Company and the terms of the Offering, including the merits and risks involved.         

 

II.          REPRESENTATIONS
AND WARRANTIES OF THE COMPANY

 

In the event that the Company accepts the
Subscriber’s subscription of Shares hereunder, the Company hereby represents and warrants to the Subscriber that:

 

2.1           Organization,
Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under
the laws of British Columbia and has full corporate power and authority to own, lease and operate its property and assets, and
to conduct its business as now conducted. The Company has conducted and is conducting its business in compliance in all material
respects with all applicable laws, rules and regulations of the jurisdictions in which it carries on business.

 

2.2           Capitalization
and Voting Rights. The Company is authorized to issue an unlimited number of common shares in the capital of the Company (the
“Common Shares”). As of March 31, 2016, the Company had 11,006,988 Common Shares issued and outstanding, and
all issued and outstanding shares of the Company are validly issued, fully paid and non-assessable. As of March 31, 2016, the
Company had: (i) warrants to purchase a total of 1,749,464 Common Shares outstanding and (ii) 2,417,255 options outstanding. Other
than as set forth in the preceding sentence, there are no outstanding options, warrants, agreements, convertible securities, preemptive
rights or other rights to subscribe for or to purchase any shares in the capital stock of the Company. Except as required by law,
there are no restrictions upon the voting or transfer of any of the shares in the capital stock of the Company pursuant to the
Company’s notice of articles as amended to date or any agreement or other instruments to which the Company is a party or
by which the Company is bound.

 

    	 	-7-	 

     

    

 

2.3           Authorization;
Enforceability. The Company has all corporate right, power and authority to enter into this Agreement and to consummate the
transactions contemplated hereby. All corporate action on the part of the Company and its directors necessary for the (i) authorization,
execution, delivery and performance of this Agreement by the Company; and (ii) authorization, sale, issuance and delivery
of the Shares contemplated hereby and the performance of the Company’s obligations hereunder has been taken or will be taken
prior to the applicable Closing (in accordance with Section 3.1 or Section 3.3, as the case may be). This Agreement has been duly
executed and delivered by the Company and constitutes a legal, valid and binding obligation of the Company, enforceable against
the Company in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief
of debtors and rules of law governing specific performance, injunctive relief or other equitable remedies, and to limitations
of public policy. The Shares, when issued and fully paid for in accordance with the terms of this Agreement, will be validly issued,
fully paid and non-assessable. The issuance and sale of the Shares contemplated hereby will not give rise to any preemptive rights
or rights of first refusal on behalf of any person which have not been waived in connection with this Offering.

 

2.4           No
Conflict; Governmental Consents.

 

(a)          The
execution and delivery by the Company of this Agreement and the consummation of the transactions contemplated hereby will not
result in the violation of any material law, statute, rule, regulation, order, writ, injunction, judgment or decree of any court
or governmental authority to or by which the Company is bound, or of any provision of the articles of amalgamation, as amended,
of the Company, and will not conflict with, or result in a material breach or violation of, any of the terms or provisions of,
or constitute (with due notice or lapse of time or both) a default under, any lease, loan agreement, mortgage, security agreement,
trust indenture or other agreement or instrument to which the Company is a party or by which it is bound or to which any of its
properties or assets is subject, nor result in the creation or imposition of any lien or encumbrance upon any of the properties
or assets of the Company.

 

(b)          No
consent, approval, authorization or other order of any United States or Canadian governmental authority is required to be obtained
by the Company in connection with the authorization, execution and delivery of this Agreement or with the authorization, issue
and sale of the Shares, except such consents and filings as may be required to be made with or obtained from the SEC, FINRA, the
TSX, the OTCOB and with any state or foreign blue sky or other Securities Regulatory Authority and any Canadian Securities Regulatory
Authority, all of which filings or consents, including the TSX Approval (as defined herein), have been or will be timely made
or obtained on or prior to Closing (for the avoidance of doubt, other than as set forth in Section 2.9).

 

2.5           Litigation.
There is no pending or, or to the knowledge of the Company, threatened legal or governmental proceedings against the Company.
The Company is not a party or subject to the provisions of any order, writ, injunction, judgment or decree of any court or government
agency or instrumentality. There is no action, suit, proceeding or investigation by the Company currently pending in any court
or before any arbitrator or that the Company intends to initiate.

 

2.6           Approvals.
The Company will obtain, prior to the Closing Date, the receipt of all required third party and regulatory approvals, as applicable,
including, without limitation, the TSX Approval and no shareholder approval is required for the Company to issue the Shares.

 

2.7           Financial
Statements. The most recent annual financial statements of the Company as filed under the Company’s issuer profile on
www.sedar.com as of the date hereof (collectively, the “Financial Statements”) accurately present fairly
the financial position and condition, the results of operations and cash flows of the Company as at the dates and for the periods
indicated thereof, have been prepared in conformity with generally accepted accounting principles in the United States, applied
on a consistent basis throughout the periods involved, except as otherwise stated therein, and no material changes in such positions
have taken place since the dates and for the periods indicated thereof, save in the ordinary course of the Company’s business
or as publicly announced.

 

    	 	-8-	 

     

    

 

2.8           Reporting
Issuer in Canada; Absence of Material Changes. The Company is a reporting issuer or the equivalent thereof in British Columbia,
Alberta, Saskatchewan, Manitoba, Ontario, Quebec, New Brunswick, Nova Scotia, Prince Edward Island and Newfoundland, and is not
in default of any requirement under applicable securities legislation, statutes, regulations, and published policies and rules
of Canadian provincial securities and TSX regulations, and, in particular, without limiting the generality of the foregoing, the
Company is in compliance with its obligations to make all reports and filings, including timely disclosure of all material changes
relating to it, under such applicable securities legislation, statutes, regulations, and published policies and rules of Canadian
provincial securities laws (“Filings”), no such disclosure has been made on a confidential basis and there
is no material change relating to the Company which has occurred and with respect to which the requisite material change report
has not been filed. The Filings complied in all material respects with the requirements of applicable securities legislation,
statutes, regulations, and published policies and rules of Canadian provincial securities and TSX regulations. The Filings, as
of their respective dates, did not contain any untrue statement of material fact or omit any material fact required to be stated
therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.
No securities commission or regulatory authority in any of the provinces of Canada has issued any order preventing or suspending
trading of any securities of the Company. Except as set forth in the Filings, there has not been (i) any material adverse change
or effect on the business, assets, financial condition, prospects or results of operations of the Company (collectively, the “Business”),
(ii) any transaction that is material to the Company, (iii) any obligation, direct or contingent, that is material to the Company,
incurred by the Company or any of its subsidiaries, (iv) any change in the outstanding indebtedness of the Company and its subsidiaries
(taken as a whole) that is material to the Company or the Business, (v) any dividend declared, paid or made on the capital stock
of the Company, or (vi) any loss or damage (whether or not insured) to the property of the Company or any subsidiary which has
been sustained which in the case of this clause (vi), individually or in the aggregate, could reasonably be expected to impair
in any material respect the Company’s ability to enter into and perform on a timely basis its obligations under this Agreement.

 

2.9           Listing.
The common shares of the Company are listed on the TSX. On each Closing, the Shares issued hereunder will have been conditionally
approved for listing on the TSX (the “TSX Approval”), subject only to the satisfaction of customary deliverables
after Closing, which the Company will perform in a timely fashion, and clearance of the PIF (as defined below) by the TSX in respect
of the Second Closing Shares.

 

2.10         No
General Solicitation. Neither the Company nor, to its knowledge, any person acting on its behalf has offered or sold or will
offer or sell the Shares by any form of general solicitation or general advertising, including, but not limited to, the following:

 

(a)          any
advertisement, article, notice or other communication published in any newspaper, magazine, or similar media or broadcast over
television or radio; and

 

(b)          any
seminar or meeting whose attendees have been invited by any general solicitation or general advertising.

 

2.11         No
Fees. No brokerage, agency, finder or other fiscal advisory or similar fee is payable by the Company in connection with the
transactions contemplated herein.

 

2.12         Investment
Company. The Company is not an “investment company” within the meaning of such term under the Investment Company
Act of 1940, as amended, and the rules and regulations of the SEC thereunder.

 

    	 	-9-	 

     

    

 

2.13         Disclosure.
The representations and warranties made by the Company in this Agreement and the Filings when read together do not contain any
untrue statement of a material fact and do not omit to state a material fact necessary to make the statements herein as a whole
not misleading.

 

III.         TERMS
OF SUBSCRIPTION

 

3.1           The
Company will conduct the purchase and sale of the First Closing Shares on the First Closing Date whereupon:

 

(a)          the
Subscriber shall deliver to the Company, if not previously delivered: (i) this duly completed and executed Agreement and the applicable
Accredited Investor Certificate; and (ii) the portion of the Purchase Price payable for the First Closing Shares by wire
transfer to an account designated by the Company Counsel (collectively, the “Subscriber Deliverables”); and

 

(b)          the
Company will deliver to the Subscriber at or prior to the First Closing Date (unless otherwise specified below):

 

		(i)	a certificate of good standing
                                         of the Company issued by the British Columbia Registrar of Companies dated no later than
                                         one (1) business day before the First Closing Date;

		(ii)	an officer’s certificate
                                         of the Company, dated as of the First Closing Date, as to: (I) the resolutions of the
                                         Board then in full force and effect authorizing the execution, delivery and performance
                                         of this Agreement to be executed by the Company and the transactions contemplated thereby;
                                         (II) the incumbency and signatures of those of its officers authorized to act with respect
                                         to this Agreement to be executed by such person; and (III) the full force and validity
                                         of each organizational document of the Company and copies thereof;

		(iii)	a closing certificate, dated
                                         as of the First Closing Date and duly executed and delivered by the Chief Executive Officer
                                         or Chief Financial Officer of the Company, certifying for and on behalf of the Company
                                         and not in their personal capacities, to the best of the knowledge, information and belief
                                         of the persons so signing, after having made due enquiry, that: (I) the Company has complied
                                         in all material respects with all the covenants and satisfied all the terms and conditions
                                         of this Agreement on its part to be complied with and satisfied at or prior to the First
                                         Closing Date and (II) the representations and warranties of the Company contained herein
                                         are true and correct in all respect as at the First Closing Date;

		(iv)	evidence of receipt of the TSX
                                         Approval;

		(v)	a copy of this Agreement duly
                                         executed by the Company;

		(vi)	an opinion of Company Counsel
                                         in a form acceptable to the Subscriber in respect of the First Closing Shares; and

		(vii)	within two (2) business days
                                         after the First Closing Date, a certificate registered in the name of the Subscriber
                                         (or as directed by it) duly executed and delivered by the Company, representing the First
                                         Closing Shares purchased hereunder free and clear of all liens, security interests, claims
                                         and encumbrances (and in this regard the Subscriber hereby authorizes and directs the
                                         Company to deliver the certificate representing the First Closing Shares purchased by
                                         the Subscriber pursuant to this Agreement to the address indicated on the signature page
                                         hereto) (items (i) through (vii) collectively, the “First Closing Company Deliverables”).

 

    	 	-10-	 

     

    

 

3.2           On,
or as soon as practicable after, the First Closing Date, the relevant affiliate of the Subscriber shall submit to the TSX a
duly completed and executed Personal Information Form (the “PIF”) and will take all reasonable
actions in connection with having the PIF cleared by the TSX.

 

3.3           The
Company will conduct the purchase and sale of the Second Closing Shares on the Second Closing Date whereupon:

 

(a)          the
Subscriber shall deliver to the Company the portion of the Purchase Price for the Second Closing Shares by wire transfer to an
account designated by the Company Counsel; and

 

(b)          the
Company will deliver to the Subscriber at or prior to the Second Closing Date (unless otherwise specified below):

 

		(i)	a certificate of good standing
                                         of the Company issued by the British Columbia Registrar of Companies dated no later than
                                         one (1) business day before the Second Closing Date;

		(ii)	an officer’s certificate
                                         of the Company, dated as of the Second Closing Date, as to: (I) the resolutions of the
                                         Board then in full force and effect authorizing the execution, delivery and performance
                                         of this Agreement to be executed by the Company and the transactions contemplated thereby;
                                         (II) the incumbency and signatures of those of its officers authorized to act with respect
                                         to this Agreement to be executed by such person; and (III) the full force and validity
                                         of each organizational document of the Company and copies thereof;

		(iii)	a bring-down certificate, dated
                                         as of the Second Closing Date and duly executed and delivered by the Chief Executive
                                         Officer or Chief Financial Officer of the Company, certifying for and on behalf of the
                                         Company and not in their personal capacities, to the best of the knowledge, information
                                         and belief of the persons so signing, after having made due enquiry, that: (I) the Company
                                         has complied in all material respects with all the covenants and satisfied all the terms
                                         and conditions of this Agreement on its part to be complied with and satisfied at or
                                         prior to the Second Closing Date and (II) the representations and warranties of the Company
                                         contained herein are true and correct in all respect as at the Second Closing Date, except
                                         as disclosed in an exhibit to such certificate and none of such disclosures, alone or
                                         in the aggregate, constitute a material adverse change to the business, assets or results
                                         of operation of the Company;

		(iv)	evidence of receipt of TSX clearance
                                         of the PIF;

		(v)	an opinion of Company Counsel
                                         in a form acceptable to the Subscriber in respect of the Second Closing Shares; and

		(vi)	within two (2) business days
                                         after the Second Closing Date, a certificate registered in the name of the Subscriber
                                         (or as directed by it) duly executed and delivered by the Company, representing the Second
                                         Closing Shares purchased hereunder free and clear of all liens, security interests, claims
                                         and encumbrances (and in this regard the Subscriber hereby authorizes and directs the
                                         Company to deliver the certificate representing the Second Closing Shares purchased by
                                         the Subscriber pursuant to this Agreement to the address indicated on the signature page
                                         hereto) (items (i) through (vi) collectively, the “Second Closing Company Deliverables”,
                                         which together with the First Closing Company Deliverables shall constitute “Company
                                         Deliverables”, as the context requires).

 

    	 	-11-	 

     

    

 

IV.          CONDITIONS
TO CLOSINGS

 

4.1           If,
prior to the Closing, the terms and conditions contained in this Agreement have not been complied with to the satisfaction of
the Subscriber, the Company and the Subscriber will have no further obligations under the Agreement.

 

4.2           The
Subscriber’s obligation to purchase the First Closing Shares on the First Closing Date is subject to the fulfillment of
certain conditions, which conditions may be waived at the option of the Subscriber to the extent permitted by law, as follows:

 

(a)          Representations
and Warranties Correct. The representations and warranties made by the Company in Article II hereof shall be true and correct
in all material respects as at the Closing Date.

 

(b)          Covenants.
All covenants, agreements and conditions contained in this Agreement to be performed by the Company on or prior to the Closing
Date shall have been performed or complied with in all material respects.

 

(c)          No
Legal Order Pending. There shall not then be in effect any legal or other order enjoining or restraining the transactions
contemplated by this Agreement.

 

(d)          No
Law Prohibiting or Restricting Such Sale. There shall not be in effect any law, rule or regulation prohibiting or restricting
the sale of the First Closing Shares (except as otherwise referred to in this Agreement) or requiring any consent or approval
of any person (including the TSX), which shall not have been obtained, to issue the First Closing Shares (except as referred to
in this Agreement).

 

(e)          TSX
Listing. The TSX shall have conditionally approved the listing of the Shares, subject only to the satisfaction by the Company
of customary post-closing conditions imposed by the TSX in similar circumstances and clearance of the PIF referred to in Section
3.2 and without the requirement of the Company to obtain shareholder approval for the Offering.

 

(f)          Company
Deliverables. The Company shall have delivered to the Subscriber all First Closing Company Deliverables (other than a certificate
representing the First Closing Shares, which may be delivered after the First Closing Date in accordance with Section 3.1(b)).

 

(g)          Opinion.
The Subscriber shall have received an opinion from Company Counsel as to customary Canadian corporate and securities matters in
relation to the First Closing Shares in a form acceptable to the Subscriber, acting reasonably.

 

4.3           The
Company’s obligation to sell the First Closing Shares on the First Closing is subject to the fulfillment of certain conditions,
which conditions may be waived at the option of the Company to the extent permitted by law, as follows:

 

    	 	-12-	 

     

    

 

(a)          Representations
and Warranties Correct. The representations and warranties made by the Subscriber in Article I
hereof shall be true and correct in all material respects.

 

(b)          Payment
of Purchase Price. The Subscriber shall have delivered to the Company the Purchase Price for the First Closing Shares purchased
by it pursuant to Section 3.1(a).

 

(c)          No
Legal Order Pending. There shall not then be in effect any legal or other order enjoining or restraining the transactions
contemplated by this Agreement.

 

(d)          No
Law Prohibiting or Restricting Such Sale. There shall not be in effect any law, rule or regulation prohibiting or restricting
the sale of the First Closing Shares or requiring any consent or approval of any person, which shall not have been obtained, to
issue the First Closing Shares (except as otherwise provided in this Agreement).

 

(e)          TSX
Listing. The TSX shall have conditionally approved the listing of the Shares subject only to the satisfaction by the Company
of customary post-closing conditions imposed by the TSX in similar circumstances, and without the requirement of the Company to
obtain shareholder approval for the Offering.

 

(f)          Subscriber
Deliverables. The Subscriber shall have delivered to the Company all Subscriber Deliverables.

 

4.4           The
Subscriber’s obligation to purchase the Second Closing Shares on the Second Closing Date is subject to the fulfillment of
certain conditions, which conditions may be waived at the option of the Subscriber to the extent permitted by law, as follows:

 

(a)          Cleared
PIF. The TSX has confirmed that the PIF referred to in Section 3.2 has been cleared by the TSX.

 

(b)          No
Legal Order Pending. There shall not then be in effect any legal or other order enjoining or restraining the transactions
contemplated by this Agreement.

 

(c)          No
Law Prohibiting or Restricting Such Sale. There shall not be in effect any law, rule or regulation prohibiting or restricting
the sale of the Second Closing Shares (except as otherwise referred to in this Agreement) or requiring any consent or approval
of any person (including the TSX), which shall not have been obtained, to issue the Second Closing Shares (except as referred
to in this Agreement).

 

(d)          Company
Deliverables. The Company shall have delivered to the Subscriber all Company Deliverables (other than a certificate representing
the Second Closing Shares, which may be delivered after the Second Closing Date in accordance with Section 3.3(b)).

 

(e)          Opinion.
The Subscriber shall have received an opinion from Company Counsel as to customary Canadian corporate and securities matters in
relation to the Second Closing Shares in substantially the same form as delivered on the First Closing Date.

 

4.5           The
Company’s obligation to sell the Second Closing Shares on the Second Closing is subject to the fulfillment of certain conditions,
which conditions may be waived at the option of the Company to the extent permitted by law, as follows:

 

    	 	-13-	 

     

    

 

(a)          Payment
of Purchase Price. The Subscriber shall have delivered to the Company the Purchase Price for the Second Closing Shares in
accordance with Section 3.3(a).

 

(b)          Cleared
PIF. The TSX has confirmed that the PIF referred to in Section 3.2 has been cleared by the TSX.

 

(c)          No
Legal Order Pending. There shall not then be in effect any legal or other order enjoining or restraining the transactions
contemplated by this Agreement.

 

(d)          No
Law Prohibiting or Restricting Such Sale. There shall not be in effect any law, rule or regulation prohibiting or restricting
the sale of the Second Closing Shares (except as otherwise referred to in this Agreement) or requiring any consent or approval
of any person (including the TSX), which shall not have been obtained, to issue the Second Closing Shares (except as referred
to in this Agreement).

 

		V.	COVENANTS

 

5.1           In
the event the Subscriber shall become a “control person” as such term is defined in the Securities Act (Ontario)
for reasons other than having acquired voting rights (within such meaning of the definition of “control person”) with
respect to Common Shares other than the Shares acquired under this Agreement, the Subscriber may, by written notice (the “Demand
Notice”), require the Company to prepare and file the necessary offering documents with one or more Canadian securities
regulatory authorities or otherwise to qualify the Shares for distribution in one or more Canadian reporting jurisdictions (a
“Demand Registration”), and the Company will otherwise take or cause to be taken all actions as may be necessary
or desirable, in order to effect a public offering of the Shares by the Subscriber (a “Secondary Offering”).
The Demand Notice shall state: (a) the number of Shares the Subscriber wishes to sell in the Secondary Offering; (b) describe
the nature or methods of the proposed distribution thereof; and (c) specify the Canadian reporting jurisdictions in which such
distribution shall be made, provided that the Company is, on the date of giving of the Demand Notice, a reporting issuer in each
such Canadian reporting jurisdiction. The Subscriber shall send the Demand Notice to the Company.

 

5.2           The
Company shall not be obliged to effect a Demand Registration in the event the Board determines in its good faith judgment that
either (i) the effect of the filing of a prospectus would materially adversely affect the Company including materially adversely
affecting the ability of the Company to consummate a material financing, acquisition, corporate reorganization, merger or other
material transaction involving the Company being considered at the time of the receipt of the request for the Demand Registration;
or (ii) there exists at the time material non-public information relating to the Company the disclosure of which the Company believes
would be detrimental to the Company and the Company has bona fide business purposes for preserving such information as confidential
(a “Valid Business Reason”), provided that in either case the Company’s obligations under this Article
 Error! Reference source not found. will be deferred for a period of not more than
90 days from the date of receipt of the Demand Notice, provided that the Company may not defer its obligations under this Article
 Error! Reference source not found. for a period of more than 120 days in any 12 consecutive
months. The Company will give written notice of the Board’s determination to postpone filing and of the fact that the Valid
Business Reason for such postponement no longer exists, in each case, promptly after the occurrence thereof. If the Company postpones
the filing of a prospectus pursuant to this Section  5.2 and if the Subscriber that initiated
the Demand Registration, at any time prior to receiving the Company’s written notice that the Valid Business Reason for
such postponement no longer exists, advises the Company in writing that it has determined to withdraw such request for a Demand
Registration, then such Demand Registration and the request therefor will be deemed to be withdrawn and such request will be deemed
not to have been given for purposes of determining whether the Subscriber exercised its right to a Demand Registration pursuant
to this Article  Error! Reference source not found., and the reasonable fees, expenses
and disbursements of legal counsel to the Subscriber incurred up to the date of withdrawal that would have been considered distribution
expenses had such Demand Registration been completed, shall be paid by the Company.

 

    	 	-14-	 

     

    

 

5.3           At
any time, the Subscriber shall be entitled, upon notice in writing to the Company, to withdraw such Demand Notice; provided, however,
that the Subscriber shall pay all of the out of pocket expenses reasonably incurred by the Company in connection with the proposed
Secondary Offering. Notwithstanding the foregoing, if and only if, the Subscriber withdraws the Demand Notice after having learned
of a material adverse change in the condition, business or business prospects of the Company, then the Subscriber will not be
required to pay any such expenses or forfeit the right to one Demand Registration.

 

5.4           In
connection with a Secondary Offering, all distribution expenses shall be borne by the Subscriber and the Company in proportion
to the amount the gross proceeds received by the Subscriber and the Company bear to the total gross proceeds of the Secondary
Offering, provided that the Company shall not be responsible for the fees and disbursements of any legal counsel to the Subscriber.
If the Company is participating in the Demand Registration then the Company shall be responsible for all fees and disbursements
of legal counsel to the Company otherwise the Subscriber shall pay the fees and disbursements of legal counsel to the Company
proportionately based on the gross proceeds received by the Subscriber.

 

5.5           The
Company shall not be obliged to effect more than three (3) Demand Registrations in any twelve (12) month period pursuant to this
Article Error! Reference source not found.. The Subscriber shall not be permitted to exercise its Demand Registration rights
pursuant to this Article Error! Reference source not found. prior to one hundred and eighty (180) days following the date
of this Agreement and in any event more than once in any one hundred and eighty (180) day period.

 

5.6           Following
the Second Closing Date, so long as the Subscriber owns at least 1,315,790 Shares (subject to adjustment in the event of any share
split, consolidation, share dividend or the like), the Subscriber shall also have unlimited registration rights relating to the
inclusion of their Shares in any prospectus filed by the Company in one or more of the Canadian reporting jurisdictions (a “Primary
Offering”). At least twenty (20) days prior to the initial filing of a preliminary prospectus for a Primary Offering,
the Company will give written notice to the Subscriber of its intention to do so. Upon the written request of the Subscriber given
within ten (10) days after the Company provides such notice (which request will state the number of Shares that is proposed to
be included in such preliminary prospectus by the Subscriber (the “Piggy Back Shares”), the Company will cause
all such Piggy Back Shares to be qualified for sale under the preliminary prospectus for a Primary Offering (a “Piggy
Back Registration”); provided that the Company will have the right to postpone or withdraw any Piggy Back Registration
initiated by the Company prior to a receipt being issued for a preliminary prospectus pursuant to this Section 5.6 without obligation
to the Subscriber. If the Company withdraws any registration initiated by it, for whatever reason, the Subscriber may initiate
a Demand Registration, subject to, and in accordance with, the provisions of Article Error! Reference source not found.
hereof.

 

5.7           The
Company will pay all distribution expenses in connection with each Piggy Back Registration and the Subscriber will pay all selling
expenses of the Subscriber, in proportion to the gross proceeds received by the Subscriber from any Piggy Back Registration.

 

    	 	-15-	 

     

    

 

5.8           Following
the Second Closing Date, so long as the Subscriber owns at least 1,315,790 Shares (subject to adjustment in the event of any share
split, consolidation, share dividend on the like), in the event the Company wishes to complete a private or public bona fide
equity financing (an “Equity Financing”), the Company shall provide the Subscriber with reasonable notice
of and the opportunity to participate in such Equity Financing so as to maintain its then pro rata voting interest in the
Company; provided, however, that in no event shall this Section 5.8: (i) permit the Subscriber to acquire securities which represent,
together with the securities owned or controlled by the Subscriber immediately prior to the Equity Financing, more than 19.9%
of the outstanding voting securities of the Company upon completion of the Equity Financing; or (ii) permit the Subscriber to
acquire securities to the extent that the TSX would require the Company to seek and obtain security holder approval as contemplated
by Section 604 of the TSX Company Manual for the Equity Financing (and, absent such level of Subscriber participation, security
holder approval would not be required).

 

VI.          Trading
in COMPANY Securities

 

6.1           The
Subscriber covenants and agrees that it will not purchase, sell, short, or engage in any securities transactions relating to the
Shares whatsoever (or advise any others to do so) while in possession of material non-public information regarding the Company,
including that it is contemplating the Offering.

 

VII.         SURVIVAL

 

7.1           The
representations and warranties contained in this Agreement and in each applicable Accredited Investor Certificate attached hereto
shall survive for a period of two (2) years after the Second Closing Date (and if none, the First Closing Date) and continue in
full force and effect and be binding upon the Company and the Subscriber, notwithstanding the completion of the purchase of the
Shares by the Subscriber pursuant hereto, or the subsequent disposition of the Shares by the Subscriber. For greater certainty,
all covenants under this Agreement shall survive the execution and delivery of this Agreement and the Closing indefinitely.

 

VIII.         MISCELLANEOUS

 

8.1           Any
notice or other communication given hereunder shall be deemed sufficient if in writing and sent by registered or certified mail,
return receipt requested, or delivered by hand against written receipt therefor, addressed as follows:

 

if to the
Company, to it at:

 

Fennec Pharmaceuticals Inc.

PO Box 13628

68 TW Alexander Drive

Research Triangle Park, NC 27709

Attention: Rosty Raykov, President
and Chief Executive Officer

 

if to the Subscriber, to the Subscriber’s
address indicated on the signature page of this Agreement.

 

Notices shall be deemed to have been given
or delivered on the date of mailing, except notices of change of address, which shall be deemed to have been given or delivered
when received.

 

8.2           Except
as otherwise provided herein, this Agreement shall not be changed, modified or amended except in writing signed by the parties
to be charged, and this Agreement may not be discharged except by performance in accordance with its terms or in writing signed
by the party to be charged.

 

    	 	-16-	 

     

    

 

8.3           This
Agreement shall be binding upon and inure to the benefit of the parties hereto and to their respective heirs, legal representatives,
successors and assigns. This Agreement, together with the schedules hereto, sets forth the entire agreement and understanding
between the parties as to the subject matter hereof and merges and supersedes all prior discussions, agreements and understandings
of any and every nature among them.

 

8.4           Upon
the execution and delivery of this Agreement by the Subscriber, this Agreement shall become a binding obligation of the Subscriber
with respect to the purchase of Shares as herein provided.

 

8.5           All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the Province of British Columbia, without regard to the principles of conflicts
of law thereof. Each party hereby irrevocably waives personal service of process and consents to process being served in any such
suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of
delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right
to serve process in any other manner permitted by law. The parties hereby waive all rights to a trial by jury. If either party
shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or
proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred
with the investigation, preparation and prosecution of such action or proceeding.

 

8.6           The
holding of any provision of this Agreement to be invalid or unenforceable by a court of competent jurisdiction shall not affect
any other provision of this Agreement, which shall remain in full force and effect. If any provision of this Agreement shall be
declared by a court of competent jurisdiction to be invalid, illegal or incapable of being enforced in whole or in part, such
provision shall be interpreted so as to remain enforceable to the maximum extent permissible consistent with applicable law and
the remaining conditions and provisions or portions thereof shall nevertheless remain in full force and effect and enforceable
to the extent they are valid, legal and enforceable, and no provisions shall be deemed dependent upon any other covenant or provision
unless so expressed herein.

 

8.7           It
is agreed that a waiver by either party of a breach of any provision of this Agreement shall not operate, or be construed, as
a waiver of any subsequent or other breach by that same party.

8.8           The
parties agree to execute and deliver all such further documents, agreements and instruments and take such other and further action
as may be necessary or appropriate to carry out the purposes and intent of this Agreement.

 

8.9           This
Agreement may be executed in two or more counterparts, including via facsimile or PDF, each of which shall be deemed an original,
but all of which shall together constitute one and the same instrument.

 

8.10         Nothing
in this Agreement shall create or be deemed to create any rights in any person or entity not a party to this Agreement. The Subscriber
hereby acknowledges and agrees that it shall bear all costs and expenses incurred by it (including any fees and disbursements
of any special counsel retained by it) relating to the sale of the Shares to the Subscriber.

 

    	 	-17-	 

     

    

 

IX.          CONFIDENTIAL
INVESTOR QUESTIONNAIRE

 

9.1           The
Subscriber represents that it is an “accredited investor” within the meaning of Rule 501(a) of Regulation D under
the Act because it comes within any of the following categories at each time of the sale of the Shares to the Subscriber (please
initial beside the categories below applicable to the Subscriber). The undersigned agrees to furnish any additional information
which the Company deems necessary in order to verify the answers set forth below:

 

_____any bank as defined in Section
3(a)(2) of the Securities Act, or any savings and loan association or other institution as defined in Section 3(a)(5)(A) of such
Act whether acting in its individual or fiduciary capacity, any broker or dealer registered pursuant to Section 15 of the United
States Securities Exchange Act of 1934, as amended, any insurance company as defined in Section 2(a)(13) of the Securities Act,
any investment company registered under the U.S. Investment Company Act of 1940 or a business development company as defined in
Section 2(a)(48) of the U.S. Investment Company Act of 1940, any small business investment company licensed by the U.S. Small
Business Administration under Section 301(c) or (d) of the U.S. Small Business Investment Act of 1958, any plan established and
maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions for
the benefit of its employees, if such plan has total assets in excess of $5,000,000, any employee benefit plan within the meaning
of the U.S. Employee Retirement Income Security Act of 1974, if the investment decision is made by a plan fiduciary, as defined
in Section 3(21) of the U.S. Employee Retirement Income Security Act of 1974, which is either a bank, savings and loan association,
insurance company, or registered investment adviser, or if the employee benefit plan has total assets in excess of $5,000,000
or, if a self-directed plan, with investment decisions made solely by persons that are accredited investors;

 

_____any private business development
company as defined in Section 202(a)(22) of the U.S. Investment Advisers Act of 1940;

 

_____any organization described in
Section 501(c)(3) of the U.S. Internal Revenue Code, corporation, Massachusetts or similar business trust, or partnership, not
formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000;

 

_____any director, executive officer,
or general partner of the issuer of the securities being offered or sold, or any director, executive officer, or general partner
of a general partner of that issuer;

 

_____any natural person whose individual
net worth, or joint net worth with that person's spouse, at the time of his purchase exceeds $1,000,000 (excluding such person’s
primary residence) ;

 

_____any natural person who had an
individual income in excess of $200,000 in each of the two most recent years or joint income with that person's spouse in excess
of $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year;

 

_____any trust, with total assets
in excess of $5,000,000, not formed for the specific purpose of acquiring the securities offered, whose purchase is directed by
a sophisticated person as described in Rule 506(b)(2)(ii) of Regulation D under the Securities Act; or

 

_____any entity in which all of the
equity owners are accredited investors.

 

The undersigned agrees that the undersigned
will notify the Company at any time on or prior to either Closing, in the event that the representations and warranties in this
Agreement shall cease to be true, accurate and complete.

 

9.2           SUITABILITY
(please answer each question)

 

    	 	-18-	 

     

    

 

		(a)	For an individual Subscriber, please
                                         describe your current employment, including the company by which you are employed and
                                         its principal business:

 

 

  

 

 

 

 

 

 

		(b)	For an individual Subscriber, please
                                         describe any college or graduate degrees held by you:

 

 

 

 

 

 

 

 

 

(c)For all Subscribers,
please list types of prior investments:

 

 

 

 

 

 

 

 

 

		(d)	For all Subscribers, please state
                                         whether you have you participated in other private placements before:

 

	YES	 	 	NO	 

 

		(e)	If your answer to question (d)
                                         above was “YES”, please indicate frequency of such prior participation in
                                         private placements of:

 

	 	 	Public

    Companies	 	Private

    Companies	 	Public or Private

    Biotechnology Companies
	Frequently	 	 	 	 	 	 
	Occasionally	 	 	 	 	 	 
	Never	 	 	 	 	 	 

 

		(f)	For individual Subscribers, do
                                         you expect your current level of income to significantly decrease in the foreseeable
                                         future:

 

	YES	 	 	NO	 

 

		(g)	For trust, corporate, partnership
                                         and other institutional Subscribers, do you expect your total assets to significantly
                                         decrease in the foreseeable future:

 

	YES	 	 	NO	 

 

    	 	-19-	 

     

    

 

		(h)	For all Subscribers, do you have
                                         any other investments or contingent liabilities which you reasonably anticipate could
                                         cause you to need sudden cash requirements in excess of cash readily available to you:

 

	YES	 	 	NO	 

 

		(i)	For all Subscribers, are you familiar
                                         with the risk aspects and the non-liquidity of investments such as the securities for
                                         which you seek to purchase?

 

	YES	 	 	NO	 

 

		(j)	For all Subscribers, do you understand
                                         that there is no guarantee of financial return on this investment and that you run the
                                         risk of losing your entire investment?

 

	YES	 	 	NO	 

 

9.3           MANNER IN
WHICH TITLE IS TO BE HELD. (circle one)

 

(a)          Individual Ownership

(b)          Community Property

(c)          Joint Tenant with Right
of Survivorship (both parties must sign)

(d)          Partnership*

(e)          Tenants in Common

(f)           Company*

(g)          Trust*

(h)          Other

 

*If Shares are being
purchased for by an entity, a Certificate of Signatory must also be completed.

 

9.4           FINRA AFFILIATION.

 

Are you affiliated or associated with
an FINRA member firm (please check one):

 

	YES	 	 	NO	 

 

If Yes, please describe:

_________________________________________________________

_________________________________________________________

_________________________________________________________

 

*If Subscriber is a Registered Representative
with an FINRA member firm, have the following acknowledgment signed by the appropriate party:

 

    	 	-20-	 

     

    

 

The undersigned FINRA member firm acknowledges
receipt of the notice required by the Rules of Conduct.

 

	 	 
	Name of FINRA Member Firm	 
	 	 
	By:	 	 
	 	Authorized Officer	 
	 	 	 
	Date:	 	 

 

9.5           The
undersigned is informed of the significance to the Company of the foregoing representations and answers contained in the Confidential
Investor Questionnaire contained in this Article IX and such answers have been provided under the assumption that the Company
will rely on them.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

    	 	-21-	 

     

    

 

Name of Subscriber: _________________________________________________

 

	 	 
	Signature	 
	 	 
	 	 
	Name Typed or Printed	 
	 	 
	 	 
	Address	 
	 	 
	 	 
	Country, City, State and Zip Code	 
	 	 
	 	 
	Telephone	 
	 	 
	 	 
	Facsimile	 
	 	 
	 	 
	Tax ID # or Social Security #	 

 

Name in which Shares should be issued:
 ______________________________

 

Dated: __________________ _____, 2016

 

    	 	 	 

     

    

 

This Agreement is agreed to and accepted
as of __________________ _____, 2016.

 

	 	 	FENNEC
    PHARMACEUTICALS Inc.
	 	 	 
	 	 	By:	 
	 	 	Name:  
	 	 	Title:

 

    	 	-23-	 

     

    

 

SCHEDULE “A”

SUMMARY OF OFFERING TERMS

 

Confidential

 

This confidential term sheet summarizes
the principal terms of a proposed equity financing by Fennec Pharmaceuticals Inc. Except as described below next to the heading,
Confidentiality/No Trading (which is intended to binding on proposed investors), this term sheet is for discussion purposes only;
there is no obligation on the part of any negotiating party until definitive transaction documents are signed. 

 

New Issue

 

TERM SHEET

Private
Placement of COMMON Shares

 

	Issuer:	Fennec Pharmaceuticals Inc. (the “Company”).
	 	 
	Offering:	Private placement of up to 2,631,579 common shares in the capital of
    the Company (the “Shares”)
	 	 
	Offering Size:	USD$5,000,000.10
	 	 
	Issue Price:	USD$1.90 per Share 
	 	 
	Use of Proceeds:	The Company intends to use the net proceeds of the Offering for STS
    development and general corporate purposes. 
	 	 
	Hold Period:	No prospectus or offering memorandum will be prepared. The Shares will
    be subject to certain hold periods in the United States pursuant to US securities laws and a hold period of four months and
    a day following the Closing Date pursuant to Canadian securities laws.
	 	 
	Listing:	The Company’s common shares are listed on the TSX (FRX) and, in
    the United States, are quoted on OTC (FENCF).  The Company will obtain the necessary approvals to list the Shares
    issued under this Offering on the TSX. 
	 	 
	Closing Date:	As soon as practicable following regulatory approval (the “Closing
    Date”). 
	 	 
	Confidentiality/No Trading:	Investor understands and agrees that this Term Sheet, and the information
    set forth herein, constitutes confidential information and, accordingly, each investor agrees not to purchase, sell, short
    or engage in any securities transactions relating to the Company’s securities whatsoever (or advise others to do so)
    in violation of applicable securities laws. 

 

    	 	-24-	 

     

    

 

SCHEDULE “B”

REGULATION “S” RESALE
REPRESENTATION LETTER

 

Fennec Pharmaceuticals Inc.

PO Box 13628

68 TW Alexander Drive

Research Triangle Park, NC 27709

Attention: President and Chief Executive
Officer

 

To Whom It May Concern:

 

The undersigned (A) acknowledges
that the sale of the securities of Fennec Pharmaceuticals Inc. (the “Company”) to which this declaration relates
is being made in reliance on Rule 904 of Regulation S under the United States Securities Act of 1933, as amended (the
“Act”) and (B) certifies that: (1) the offer of such securities was not made to a person in the United
States and either (a) at the time the buy order was originated, the buyer was outside the United States, or the seller and
any person acting on its behalf reasonably believes that the buyer was outside the United States or (b) the transaction was
executed on or through the facilities of the Toronto Stock Exchange and neither the seller nor any person acting on its behalf
knows that the transaction has been prearranged with a buyer in the United States; (2) neither the seller (or its affiliates)
nor any person acting on its behalf engaged in any “directed selling efforts” in the United States in connection with
the offer and sale of such securities; (3) the sale is bona fide and not for the purpose of “washing off” the resale
restrictions imposed because the securities are “restricted securities” (as such term is defined in Rule 144(a)(3)
under the Act); (4) the seller does not have a short position in the securities sold and does not intend to replace the securities
sold in reliance on Rule 904 with fungible unrestricted securities; (5) the contemplated sale is not a transaction, or part of
a series of transactions which, although in technical compliance with Regulation S, is part of a plan or scheme to evade the registration
provisions of the Act; and (6) the undersigned is not an “affiliate” (as defined in Rule 405 under the Act) of the
Company. Terms used herein have the meanings given to them by Regulation S.

 

	 	 
	Name:	 
	Title:	 
	Date:	 

 

    	 	-25-	 

     

    

 

CERTIFICATE OF SUBSEQUENT SALE

 

[Name and Address of Transfer Agent]

 

		RE:	Sale of Shares of Common Stock of Fennec Pharmaceuticals
Inc. (the “Company”)

 

Dear Sir/Madam:

 

The undersigned hereby
certifies, in connection with the sale of Common Shares of the Company, that the undersigned has sold the shares in compliance
with all securities laws applicable to the undersigned.

 

	Selling Stockholder (the beneficial owner): 	 

 

	Record Holder (e.g., if held in name of nominee): 	 

 

	Restricted Stock Certificate No.(s): 	 

 

	Number of Shares Sold: 	 

 

	Date of Sale: 	 

 

	 	Very truly yours,
	 	 
	Dated: ________________________	By:	 
	 	 	 
	 	Print Name: 	 
	 	 	 
	 	Title:	 

 

		cc:	Fennec Pharmaceuticals Inc.

                                         PO Box 13628

68 TW Alexander Drive

Research Triangle Park, NC 27709

Attention: President and Chief Executive
Officer

 

    	 	-26-	 

     

    

 

SCHEDULE “C”

 

ACCREDITED INVESTOR CERTIFICATE CANADA
– NATIONAL INSTRUMENT 45-106

 

		TO:	FENNEC
                                         PHARMACEUTICALS INC.

			

 

In connection with
the subscription for Shares of Fennec Pharmaceuticals Inc. (the “Company”), the undersigned (the “Subscriber”)
hereby represents and warrants that the Subscriber is an “accredited investor” as defined in National Instrument 45-106
– Prospectus Exemptions by virtue of being (check one):

 

	 ̈	 	(a)	 	(i) except in Ontario, a Canadian
        financial institution or a bank listed in Schedule III to the Bank Act (Canada),

        (ii) in Ontario, a bank listed
        in Schedule I, II or III to the Bank Act (Canada).

        (iii) in Ontario, an association
        to which the Cooperative Credit Associations Act (Canada) applies or a central cooperative credit society for which
        an order has been made under subsection 473(1) of that Act.

        (iv) in Ontario, a loan corporation,
        trust company, trust corporation, insurance company, treasury branch, credit union, caisse populaire, financial services
        cooperative or credit union league or federation that is authorized by a statute of Canada or Ontario to carry on business
        in Canada or Ontario, as the case may be.

	 ̈	 	(b)	 	the Business Development Bank of Canada,
	 ̈	 	(c)	 	a subsidiary of any person or company referred to in clause (a) or (b), if the person or company
    owns all of the voting securities of the subsidiary, except the voting securities required by law to be owned by directors
    of that subsidiary,
	 ̈	 	(d)	 	a person or company registered under the securities legislation of a province or territory
    of Canada as an adviser or dealer, except as otherwise prescribed by regulation,
	 ̈	 	(e)	 	an individual registered under the securities legislation of a jurisdiction of Canada as a
    representative of a person referred to in paragraph (d),
	 ̈	 	(f)	 	an individual formerly registered under the securities legislation of a jurisdiction of Canada,
    other than an individual formerly registered solely as a representative of a limited market dealer under one or both of the
    Securities Act (Ontario) or the Securities Act (Newfoundland and Labrador),
	 ̈	 	(g)	 	the Government of Canada, the government of a province or territory of Canada, or any Crown
    corporation, agency or wholly owned entity of the Government of Canada or of the government of a province or territory of
    Canada,
	 ̈	 	(h)	 	a municipality, public board or commission in Canada and a metropolitan community, school
    board, the Comité de gestion de la taxe scolaire de l’Île de Montréal or an intermunicipal management
    board in Québec,
	 ̈	 	(i)	 	any national, federal, state, provincial, territorial or municipal government of or in any
    foreign jurisdiction, or any agency of that government,
	 ̈	 	(j)	 	a pension fund that is regulated by either the Office of the Superintendent of Financial Institutions
    (Canada) or a pension commission or similar regulatory authority of a province or territory of Canada,

 

    	 	-27-	 

     

    

 

	 ̈	 	(k)	 	an individual who, either alone or with a spouse, beneficially owns financial
    assets having an aggregate realizable value that, before taxes but net of any related liabilities, exceeds $1,000,000, and
    the undersigned has completed and signed the enclosed Form 45-106F9,
	 ̈	 	(l)	 	an individual who beneficially owns financial assets having an aggregate realizable value
    that, before taxes but net of any related liabilities, exceeds $5,000,000,
	 ̈	 	(m)	 	an individual whose net income before taxes exceeded $200,000 in each of the 2 most recent
    calendar years or whose net income before taxes combined with that of a spouse exceeded $300,000 in each of the 2 most recent
    calendar years and who, in either case, reasonably expects to exceed that net income level in the current calendar year,
    and the undersigned has completed and signed the enclosed Form 45-106F9,
	 ̈	 	(n)	 	an individual who, either alone or with a spouse, has net assets of at least $5,000,000,
    and the undersigned has completed and signed the enclosed Form 45-106F9,
	 ̈	 	(o)	 	a person, other than an individual or investment fund, that has net assets of at least $5,000,000
    as shown on its most recently prepared financial statements, and that has not been created or used solely to purchase or
    hold securities as an accredited investor,
	 ̈	 	(p)	 	an investment fund that distributes
        or has distributed its securities only to:

        (i)           a
        person that is or was an accredited investor at the time of the distribution,

        (ii)          a
        person that acquires or acquired securities in the circumstances referred to in sections 2.10 of National Instrument 45-106
        (“NI 45-106”) [Minimum amount investment], or 2.19 of NI 45-106 [Additional investment in investment
        funds], or

        (iii)         a
        person described in paragraph (i) or (ii) that acquires or acquired securities under section 2.18 of NI 45-106 [Investment
        fund reinvestment],

	 ̈	 	(q)	 	an investment fund that distributes or has distributed securities under a prospectus in a
    jurisdiction of Canada for which the regulator or, in Québec, the securities regulatory authority, has issued a receipt,
	 ̈	 	(r)	 	a trust company or trust corporation registered or authorized to carry on business under the
    Trust and Loan Companies Act (Canada) or under comparable legislation in a jurisdiction of Canada or a foreign jurisdiction,
    acting on behalf of a fully managed account managed by the trust company or trust corporation, as the case may be,
	 ̈	 	(s)	 	a person acting on behalf of a fully managed account managed by that person, if that person
    is registered or authorized to carry on business as an adviser or the equivalent under the securities legislation of a jurisdiction
    of Canada or a foreign jurisdiction,
	 ̈	 	(t)	 	a registered charity under the Income Tax Act (Canada) that, in regard to the trade,
    has obtained advice from an eligibility adviser or an adviser registered under the securities legislation of the jurisdiction
    of the registered charity to give advice on the securities being traded,
	 ̈	 	(u)	 	an entity organized in a foreign jurisdiction that is analogous to the entity referred to
    in paragraph (a)-(d) or (j) in form and function,

 

    	 	-28-	 

     

    

 

	 ̈	 	(v)	 	a person in respect of which all of the owners of interests, direct, indirect
    or beneficial, except the voting securities required by law to be owned by directors, are persons that are accredited investors,
	 ̈	 	(w)	 	an investment fund that is advised by a person registered as an adviser or a person that is
    exempt from registration as an adviser,
	 ̈	 	(x)	 	a person that is recognized or designated by the securities regulatory authority or, except
    in Ontario and Québec, the regulator as an accredited investor, or
	 ̈	 	(y)	 	a trust established by an accredited investor for the benefit of the accredited investor’s
    family members of which a majority of the trustees are accredited investors and all of the beneficiaries are the accredited
    investor’s spouse, a former spouse of the accredited investor or a parent, grandparent, brother, sister, child or grandchild
    of that accredited investor, of that accredited investor’s spouse or of that accredited investor’s former spouse.

 

Dated this ____ day of _____________, 2016

 

	 	Signed: 	 
	 	 	 
	 	Name:	 
	 	 	 
	 	For:	 
	 	 	 
	 	Title:	 

 

    	 	-29-	 

     

    

 

SCHEDULE “D”

 

ACCREDITED INVESTOR CERTIFICATE FOR
RESIDENTS OF 

AN INTERNATIONAL JURISDICTION

 

TO:FENNEC PHARMACEUTICALS INC.

 

Any capitalized terms not defined herein
shall have the meaning set forth in the Subscription Agreement between the undersigned and Fennec Pharmaceuticals Inc. dated on
or about the date hereof.

 

In connection with the subscription for
Shares of Fennec Pharmaceuticals Inc. (the “Company”), the undersigned (the “Subscriber”)
hereby represents, warrants and covenants (on its own behalf or, if applicable, on behalf of those for whom the Subscriber is
contracting hereunder) and certifies to the Company and acknowledges that the Company is relying thereon that:

 

General

 

		A.	The Subscriber is resident in an International Jurisdiction
                                         (as defined in the Subscription Agreement) or is subject to the laws of that International
                                         Jurisdiction;

 

		B.	The Subscriber complies with the requirements of all applicable
                                         securities laws in their International Jurisdiction and will provide such evidence of
                                         compliance with all such matters as the Company may request;

 

		C.	Upon execution of this Accredited Investor Certificate by the
                                         Subscriber, this Certificate shall be incorporated into and form a part of the Subscription
                                         Agreement;

 

		D.	The Subscriber is purchasing the Shares as principal for its
                                         own account and not for the benefit of any other person, for investment only, and will
                                         comply with all applicable securities laws and with the policies of the TSX concerning
                                         the purchase, the holding of and the resale restrictions on the securities; or is acting
                                         as agent for one or more disclosed purchasers, each disclosed purchaser is purchasing
                                         as principal for its own account and not for the benefit of any other person, for investment
                                         only, and not with a view to the resale or distribution of all or any of the Shares;

 

Prospectus Exemptions

 

		E.	The Subscriber is knowledgeable of securities legislation having
                                         application or jurisdiction over the Subscriber and the Offering (other than the laws
                                         of Canada and the U.S.) which would apply to this subscription;

 

		F.	The Subscriber is purchasing the Shares pursuant to exemptions
                                         from any prospectus, registration or similar requirements under the laws of that International
                                         Jurisdiction or, if such is not applicable, the Subscriber is permitted to purchase the
                                         Shares, and the Company does not have any filing obligations in the International Jurisdiction;
                                         and

 

		G.	No laws in the International Jurisdiction require the Company
                                         to make any filings or seek any approvals of any kind whatsoever from any regulatory
                                         authority of any kind whatsoever in the International Jurisdiction.

 

    	 	-30-	 

     

    

 

Dated this ____ day of _____________, 2016

 

	 	Signed: 	 
	 	 	 
	 	Name:	 
	 	 	 
	 	For:	 
	 	 	 
	 	Title:	 

 

    	 	-31-Exhibit 10.42

 

 

May 9, 2016

 

Purchase Agreement

 

This Purchase Agreement (this "Agreement")
is made as of May 9, 2016, and sets forth terms by Elion Oncology, LLC (the "Purchaser") 4800 Hampden Lane,
Suite 200, Bethesda, MD 20814 will acquire from Fennec Pharmaceuticals Inc., 68 TW Alexander Dr., Triangle, NC 27709, (the "Company")
all intellectual property and related property of the Company pertaining to Eniluracil and the compound known as Adh-1.

 

1.           Scope of the Agreement

 

1.1.         The scope of this Agreement shall be the
sale and purchase of the intellectual property of the Company as described in this Purchase Agreement, including any and all data,
documentation, research, rights, benefits and available substances, active pharmaceutical ingredient (API), as well as any related
kits relating to Eniluracil and Adh-1 technologies  or development programs thereunder and all other related pharmaceutical
technologies of the Company, whether owned, licensed or otherwise (collectively, the “Technologies”), including
without limitation the lead (and back-up) compounds products in clinical trials, preclinical and clinical phases (collectively,
the "Products"), data, trial master files, IND’s, safety databases on which the Technologies and
Products have been researched and/or developed by the Company, files, and discs relating to the foregoing containing information
relating to Eniluracil and Adh-1 (all such Technologies, Products and other assets of the Company collectively, the "Purchased
Assets"), whether in hard copy, electronic files, notebooks, or otherwise wherever they are stored, including:

 

		i.	All patents, copyrights, trademarks, designs, including all related applications, and any other
registered or unregistered intellectual or industrial property relating to the Products and the Technologies.

 

		ii.	All information and know-how, including but not limited to information and know-how related to
research, development, manufacturing and/or business (commercial/marketing), used or held for use in connection with the Products
and the Technologies.

 

		iii.	All health and regulatory registrations and/or applications including two open and active IND’s
for the above referenced technologies and related regulatory documentation for any and all jurisdictions for the Products and the
Technologies.

 

		iv.	All drugs, formulations and user devices, applications, and all safety data.

 

		v.	All other information, documentation, work product and goodwill related to the Products and the
Technologies.

 

    	 	1	 

     

    

 

The foregoing Purchased Assets are to be transferred
in an orderly fashion, with the Company attaching to this Agreement a list of all patents, copyrights, trademarks, designs, whether
applied for or received, and identifying the current status of each; and a list of all health and regulatory registrations and/or
applications and the current status of each. For further clarity and avoidance of doubt, this includes all regulatory communications
with the U.S. FDA and EMEA (the European Medicines Agency) and any other jurisdiction where the Company has prosecuted a development
plan for marketing authorization. For the avoidance of doubt, the parties acknowledge and agree that the GSK License Agreement
(as defined below) is not being assigned to the Purchaser as part of the Purchased Assets; rather, the Company’s developments
and commercialization rights thereunder shall be sublicensed to Purchaser.

 

1.2.         Purchaser will
acquire all of the Purchased Assets in an asset purchase pursuant to this Agreement and, except as otherwise provided herein, the
Purchaser will not be responsible for any of the Company's liabilities.

 

2.           Purchase Price

 

Within 10 days after the end of the Review Period (as defined
below) and upon satisfaction of the conditions precedent in Paragraph 3 of this Agreement, there shall be a closing (the “Closing”)
with (i) Purchaser paying the Company $40,000 (US Dollars), and (ii) the Company assigning and transferring to Purchaser the Purchased
Assets. Purchaser’s obligation to close is subject to the Company’s representations and warranties in Paragraph 5 of
this Agreement being true and correct as of the Closing, with the Company certifying in writing to the Purchaser that all such
representations and warranties are true and correct as of the Closing.

 

In addition, from and after the Closing, the Purchaser shall
also be obligated to pay to the Company in US dollars, on a quarterly basis, within thirty days following the end of each calendar
quarter (with the first calendar quarter being the period from closing until December 31, 2016) until the expiry of the last to
expire of the patents included in the Purchased Assets, an amount (the “Revenue Share Payment”) equal to five
percent (5%) of the gross amounts invoiced or otherwise earned by or paid to the Purchaser, its Affiliates (as defined below),
assignees and sublicensees that is derived from the Purchased Assets, including Adh1 or Eniluracil or any other indications, pharmaceutical
preparations or formulations derived in whole or in part from the Purchased Assets (“Purchased Asset Revenue”)
during such preceding calendar quarter. A report detailing all Purchased Asset Revenue shall accompany such quarterly payment.
.. Purchased Asset Revenue shall not include any equity investment in or loan to the Purchaser for development of, or investment
in, the Purchased Asset.

 

“Affiliate” means, with respect to any specified
person or entity, any other person or entity who, directly or indirectly, controls, is controlled by, or is under common control
with such person or entity. Purchaser shall also be solely responsible for making, and shall indemnify and hold harmless the Company
from and against, any and all milestone, royalty or other payments required to be paid from and after the Closing under this Agreement
as it relates to the Purchased Assets to GlaxoSmithKline (“GSK”) under the Development and License Agreement dated
July 14, 2015, as amended December 20, 2005, June 23, 2006, January 16, 2007 and May 23, 2007 (the “GSK License Agreement”)with
respect to the Purchased Assets. The Company shall deliver to Purchaser a copy of any correspondence, including but not limited
to email received from GSK or its counsel with respect to the Purchased Assets, and copies of any correspondence, including but
not limited to emails sent by the Company or its counsel to GSK as it relates to the Purchased Assets, within 10 days after such
correspondence is sent or received. The Company shall be solely responsible for making, and shall indemnify and hold harmless the
Purchaser from and against, any and all royalty or other payments required to be paid prior to the Closing under this Agreement
or which do not relate to the Purchaser’s purchase of the Purchased Assets.

 

    	 	2	 

     

    

 

Any development milestone payments arising after the Closing
under this Agreement and required under Section 8.1.1 of the GSK License Agreement as it relates to the Purchased Assets shall
be paid by the Purchaser. Future Revenue Share Payments shall be reduced (up to a maximum reduction of 4.0% of Purchased Assets
Revenue) by any other required payments made to GSK with respect to the Purchased Assets, it being understood and agreed that such
reduction of future Revenue Share Payments (up to a maximum reduction of 4.0% of Purchased Assets Revenue) shall be the sole remedy
and recourse in the event of such other required payment to GSK under the GSK License Agreement. In no event shall Company be responsible
for refunding any previously made Revenue Share Payments or making any payment that may be required under the GSK License Agreement,
even if such required payments exceed future Revenue Share Payments.

 

The decision whether or not to develop the Technologies in any
other additional indications or any other Products will be made by Purchaser alone, in its sole discretion.

 

3.           Conditions Precedent.

 

Closing will be subject to certain conditions being fulfilled,
including but not limited to the following:

 

3.1          The end of the Review Period, as defined in
Paragraph 4 of this Agreement;

 

3.2.         Approval of the transaction evidenced by this
Agreement by the directors and shareholders of the Company and the Members of the Purchaser and delivery of such approval to the
Company or the Purchaser, as the case may be.

 

3.3         During the period up to the closing date, no
circumstances have occurred which may have a material adverse effect on the Purchased Assets or the Company’s ability to
transfer the Purchased Assets to Purchaser.

 

3.4         That the Company has provided full disclosure of any and all material events and circumstances of the Purchased Assets,
and there are no material omissions of information.

 

    	 	3	 

     

    

 

4.           Due
Diligence. Purchaser shall have the sooner of 90 days after the date of this Agreement or completion of its due diligence
review (the “Review Period”) to evaluate the Purchased Assets. The Company shall cooperate with Purchaser’s
review of the Purchased Assets, providing the Company with access to all such assets. Prior to the end of the Review Period, the
Purchaser shall have the right to terminate this Agreement by written notice to the Company, in which event the Purchaser shall
return to the Company the Technologies, Products and Assets received from the Company and neither party shall have any further
right or obligation under this Agreement.

 

5.           Representations
and Warranties.

 

The Company hereby represents and warrants to Purchaser as follows:

 

5.1         There is no action or claim pending or threatened against
the Company or the directors of the Company which could affect the proposed sale of the Purchased Assets or other assets of the
Company to the Purchaser or impair the use of and operations related to the Purchased Assets, including Technologies and Products
after completion of the acquisition.

 

5.2         Except as set forth in Exhibit A, the Company owns the
Purchased Assets and no third party has any right, title or interest in the Purchase Assets.

 

5.3         No one has made any claim or threatened to make a claim
with respect to the Purchased Assets.

 

5.4         The Purchased Assets are being transferred to Purchaser
free and clear of any claims, liens or encumbrances.

 

5.5         The current status of any regulatory approvals with respect
to the Purchased Assets is set forth on Exhibit 1 attached hereto.

 

5.6         All licenses obtained or provided by the Company which
relate in any manner to the Purchased Assets are set forth on Exhibit 2 attached hereto. To the best of the Company’s
knowledge, information and belief, no milestone, royalties or other payments are required to be made in connection with the use,
development, licensing or sale of the Purchased Assets, except as set forth in Exhibit 2.

 

5.7         The party entering into this Agreement for the Company
has the right and authority to enter into this Agreement and this Agreement is binding and enforceable on the Company. The Company
has taken all necessary action and there are no notices, filings, consents or approvals, required to be obtained from the Company,
its shareholder or Board of Directors, from its creditors or third parties or from governmental or regulatory authorities, except
as provided in Paragraph 3 above, before this Agreement can be entered into or the Purchased Assets can be transferred to Purchaser.

 

    	 	4	 

     

    

 

5.8         No third party approval or consent is required in connection
with the Company entering into this Agreement or transferring the Purchased Assets to the Purchaser, including but not limited
to the consent of any licensor or governmental agency.

 

5.9         A correct and complete copy of the GSK License Agreement,
including any amendments or modifications thereto is attached hereto as Exhibit 3. The Company is not in breach of
the GSK License Agreement and has not received any notice of termination, breach or default under the GSK License Agreement.

 

6.           Binding Commitments.

 

6.1         Costs: Each party shall pay and be responsible for its
own costs and expenses incurred in connection with the proposed acquisition, including, without limitation, legal, accountancy,
actuarial and other professional fees.

 

6.2         Confidentiality: Any information disclosed
by one party hereto to the other party in the course of the present negotiations are strictly confidential at any times in so far
as it is not publicly known, except that it may be disclosed to advisors appointed with respect to the transactions covered by
this Agreement or as may be required with respect to governmental authorities.

 

6.3         Applicable Law and Jurisdiction: This Agreement
is governed by and shall be construed in accordance with Maryland law. The place of jurisdiction for all disputes arising from
this Agreement shall be the United States.

 

7.           Other Terms and Formalities

 

7.1          Purchaser
agrees that the Company shall have the right, at Company’s expense (except as otherwise provided below), no more than once
in any calendar year, to audit the financial records of Purchaser, its Affiliates, assignees and sublicensees as it relates to
the Purchased Assets to ensure that all Purchased Asset Revenue is recorded and all Revenue Share Payments are made in accordance
with this Agreement. Purchaser shall provide the Company with reasonable access to all financial records relating to the Purchased
Assets of the Purchaser, its Affiliates, assignees and sublicensees ; and (iii) permit Company to interview employees of the Purchaser,
its Affiliates, assignees and sublicensees as reasonably necessary to complete an audit. Such audit shall be conducted in Purchaser’s
offices during normal business hours. All information provided in connection with such audit shall be deemed confidential and shall
not be disseminated by the Company or its auditors except in an action to enforce this Agreement, and only to the extent required
to enforce this Agreement. In the event any such audit reveals underpayment of any Revenue Share Payment, Purchaser shall forthwith
pay such deficiency to Company and, if such underpayment represents 5% or more of the total Revenue Share Payment made for such
calendar quarter, such audit shall be at Purchaser’s expense. Any such audit shall be conducted by a certified public accounting
firm which is not being paid on a contingent fee basis and the costs of the same shall be borne by the Company.

 

    	 	5	 

     

    

 

7.2         This Agreement shall be binding on the parties
hereto and their successors and assigns.

 

7.3         This Agreement constitutes the entire understanding
of the parties with respect to the subject matter hereof. This Agreement may not be amended except by an instrument in writing
signed by both the Company and the Purchaser.

 

7.4         This Agreement may be executed in counterparts,
which together shall constitute one agreement.

 

7.5         Purchaser shall have the right to assign its
right, title and interest in this Agreement and/or the Purchased Assets without the consent of the Company or any third party.
Any such assignment shall not reduce or relieve Purchaser from its Revenue Share Payment obligations hereunder.

 

* * *

 

Purchaser and the Company have
executed this Agreement as of the date first hereinabove written.

 

	Fennec Pharmaceuticals, Inc.
	 	 	 	 
	By:	 	 	 
	Name Printed: Rosty Raykov
	 	 	 	 
	 	 	 	 
	Elion Oncology,
    LLC	 
	 	 	 	 
	By:	 	 	 

 

	
R.
Michael Floyd, Manager

 
	 

 

 

    	 	6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}]]